Advanced International Journal for Research

E-ISSN: 3048-7641   •   Impact Factor: 9.11

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6, Issue 6 (November-December 2025) Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 6
November-December 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

A Review on Advances in Drug Design with Epigallocatechin Gallate (EGCG): A Natural Platform for New Therapies

Author(s) Prof. Harshavardhan tanaji suryawanshi, Ms. Pradnya Niranjan Mane, Ms. Arya Kalgonda Hable
Country India
Abstract Epigallocatechin gallate (EGCG), the predominant catechin in green tea, has attracted significant attention for its wide-ranging pharmacological properties, including antioxidant, anti-inflammatory, anticancer, neuroprotective, and antimicrobial effects. Its unique polyphenolic structure offers multiple interaction sites, enabling the modulation of diverse biological pathways and molecular targets. This review explores EGCG as a promising natural scaffold for modern drug design, highlighting structural features that lend themselves to chemical modification and optimization for enhanced bioavailability, stability, and target specificity. We examine current advances in in silico modeling, structural-activity relationship (SAR) studies, and nanodelivery systems aimed at overcoming EGCG’s physicochemical limitations.[1] Special emphasis is placed on translational insights that bridge natural product pharmacology with synthetic medicinal chemistry, paving the way for innovative therapeutic agents derived from EGCG. The synthesis of existing literature underscores EGCG’s potential as a versatile molecular template for developing next-generation therapeutics across oncology, neurodegenration, infectious disease, and metabolic disorders.Current literature suggests EGCG is not only a leading candidate for developing next-generation therapeutics across oncology, neurodegeneration, cardiovascular, immune, and infectious diseases, but also a model molecule for innovative drug delivery and multi-drug systems. Future research should aim to address existing challenges in pharmacokinetics and clinical validation, paving the way for EGCG-based therapies to transition from promising natural product to clinical reality.[2]
Keywords Epigallocatechin gallate, Molecular Scaffold, Anticancer Agents, QSAR, Computer Aided Drug Design, Molecular Docking
Field Medical / Pharmacy
Published In Volume 6, Issue 6, November-December 2025
Published On 2025-11-21
DOI https://doi.org/10.63363/aijfr.2025.v06i06.2130
Short DOI https://doi.org/hbdswg
View / Download PDF File

Share this



E-ISSN 3048-7641
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About AIJFR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-79-39-59 editor@aijfr.com